Navigation Links
Genaera Corporation Announces 2008 Financial Results
Date:3/3/2009

PLYMOUTH MEETING, Pa., March 3 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced its financial results for the year and quarter ended December 31, 2008. The net loss for the year ended December 31, 2008 was $16.0 million, or $(0.92) per share basic and diluted, as compared to a net loss of $15.7 million, or $(0.90) per share basic and diluted, for the year ended December 31, 2007. The net loss for the quarter ended December 31, 2008 was $3.6 million, or $(0.20) per share basic and diluted, as compared to a net loss of $5.8 million, or $(0.33) per share basic and diluted, for the quarter ended December 31, 2007. The loss from operations for the year and quarter ended December 31, 2008 was $16.7 million and $3.6 million, respectively, as compared to $17.2 million and $6.1 million for the same periods in 2007.

Genaera's research and development expenses for the year and quarter ended December 31, 2008 were $11.7 million and $2.2 million, respectively, compared to $13.1 million and $3.6 million, respectively, for the same periods in 2007. The decrease in research and development expenses for the year ended December 31, 2008 as compared to the same period in 2007 was primarily due to a decrease in clinical, manufacturing and personnel costs as a result of the discontinuation of the EVIZON(TM) (squalamine lactate) program for the treatment of wet age-related macular degeneration and the LOMUCIN(TM) program for the treatment of cystic fibrosis in 2007. This decrease was partially offset by an increase in clinical and third-party contract research expenses related to the trodusquemine (MSI-1436) program for the treatment of type 2 diabetes and obesity and an increase in indirect expenses as a result of an increase in stock-based compensation expense, partially offset by decreases in various other expenses.

Genaera's general and administrative expenses for the year and quarter ended December 31, 2008 were $6.5 million and $1.5 million, respectively, compared to $6.8 million and $2.5 million, respectively, for the same periods in 2007. The decrease in general and administrative expenses for the year ended December 31, 2008 as compared to the same period in 2007 was due to decreases in bonus expense, legal and accounting fees, personnel expenses, realignment costs, investor and public relations expense, public company expenses and consulting fees as a result of cost cutting initiatives implemented in May 2008. The decreases were partially offset by an increase in stock-based compensation expense.

The Company's cash, cash equivalents and short-term investment balance was $8.1 million at December 31, 2008.

About Genaera

Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma. For further information, please see our website at www.genaera.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to the risks and uncertainties discussed in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at www.sec.gov as well as from other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.


                                 GENAERA CORPORATION
                             STATEMENTS OF OPERATIONS
                         (In thousands, except per share data)
                                     (Unaudited)

                                  Year Ended                Quarter Ended
                                  December 31,               December 31,
                              2008           2007         2008         2007
                              ----           ----         ----         ----
    Revenues                $1,489         $2,737          $43          $76
                            ------         ------          ---          ---

    Costs and expenses:
      Research and
       development          11,651         13,097        2,174        3,640
      General and
       administrative        6,499          6,792        1,472        2,534
                             -----          -----        -----        -----
                            18,150         19,889        3,646        6,174
                            ------         ------        -----        -----

    Loss from operations   (16,661)       (17,152)      (3,603)      (6,098)

    Interest income            391          1,278           46          268
                               ---          -----           --          ---

    Loss before income
     taxes                 (16,270)       (15,874)      (3,557)      (5,830)
                          --------       --------      -------      -------

    Income tax benefit         281            147           --           --
                               ---            ---          ---          ---

    Net loss              $(15,989)      $(15,727)     $(3,557)     $(5,830)
                         =========      =========     ========     ========

      Net loss per
       share - basic
       and diluted          $(0.92)        $(0.90)      $(0.20)      $(0.33)
                         =========      =========     ========     ========

      Weighted
       average
       shares
       outstanding
       - basic and
       diluted              17,464         17,452       17,465       17,461
                            ======         ======       ======       ======

                              CONDENSED BALANCE SHEETS
                                   (In thousands)
                                     (Unaudited)

                                        December 31, 2008    December 31, 2007
                                        -----------------    -----------------

    Cash, cash equivalents and
     short-term investments                   $8,064              $20,900
    Prepaid expenses and other
     current assets                              226                  356
    Fixed assets, net                            146                  374
    Other assets                                  --                   56
                                              ------               ------
       Total assets                           $8,436              $21,686
                                              ======              =======

    Current liabilities                       $1,036               $3,377
    Long-term liabilities                         --                   70
    Stockholders' equity                       7,400               18,239
                                               -----               ------
       Total liabilities and
        stockholders' equity                  $8,436              $21,686
                                            ========            =========


'/>"/>
SOURCE Genaera Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
2. Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
3. Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph
4. Xmark Comments on Genaera Cost-Saving Plan
5. Genaera Corporations 2008 Annual Stockholder Meeting Results
6. Genaera Receives Non-Compliance Notice From NASDAQ
7. Genaera to Present at Therapeutic Area Partnerships 2008
8. Genaera to Participate in Obesity Panel at RBC Capital Markets Healthcare Conference
9. Genaera to Present at BIO CEO & Investor Conference
10. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... Memphis, Tennessee (PRWEB) , ... February 13, 2016 ... ... Louise Herrington School of Nursing with an in-kind gift of a VeinViewer® Vision ... help students as they learn how to start an IV and draw blood, ...
(Date:2/13/2016)... ... 2016 , ... DDi , a Makro company, makes ... its expertise in eClinical Solutions. DDi has built its solution competency with a ... global clients. DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains ...
(Date:2/12/2016)... ... February 12, 2016 , ... The law firm of Morrow, ... Parishes. The purpose of these scholarships is to encourage applicants to pursue a ... seek employment within these two parishes. , “We have available jobs in St. ...
(Date:2/12/2016)... ... ... CDRH Enforcement Trends: , Back to the Future , Feb. 25, 2016 — 11:00 a.m. ... “Those who don’t learn from history are doomed to repeat it.” , An analysis of ... year. But that takes time. , Take a close look at the warning letters ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... As a ... hectic schedule, a demanding job, and no time to decompress, Rabinowitz found herself drawn ... herself to meditation for its impact on her life, implementing a 20-minute-per-day meditation practice ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... , Feb. 12, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO ) is pleased to ... Account Management and Payor Strategies effective Jan. 23, 2016. ... ... ... Diplomat Specialty Pharmacy ...
(Date:2/12/2016)... Inc., a medical device company that pioneered the use of the ... device indicated for fusion for certain disorders of the sacroiliac (SI) ... Contractor (MAC) covering the states of Connecticut , ... Massachusetts , Minnesota , ... Rhode Island , Vermont and ...
(Date:2/12/2016)... and SEOUL, South Korea ... Menarini and Macrogen, Inc. today announced they will ... innovative procedures for precision medicine in cancer. The ... Biosystems, DEPArray™ digital-sorting technology with Macrogen,s high-throughput Next ... certified under the Clinical Laboratory Improvement Amendments (CLIA) ...
Breaking Medicine Technology: